[{"address1": "Azrieli Center", "address2": "Building D 26 Harokmim Street", "city": "Holon", "zip": "5885849", "country": "Israel", "phone": "972 3 765 8585", "fax": "972 3 765 8555", "website": "https://cgen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with na\u00efve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Anat  Cohen-Dayag Ph.D.", "age": 56, "title": "CEO, President & Director", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": 796519, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zurit  Levine Ph.D.", "age": 55, "title": "Senior Vice President of Technology Innovation", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 345697, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pierre  Ferre Ph.D.", "age": 46, "title": "Vice President of Preclinical Development", "yearBorn": 1977, "fiscalYear": 2022, "totalPay": 415100, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alberto  Sessa", "age": 61, "title": "Chief Financial Officer", "yearBorn": 1962, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eran  Ophir Ph.D.", "age": 45, "title": "Chief Scientific Officer", "yearBorn": 1978, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yvonne  Naughton", "title": "Head of Investor Relations & Corporate Communications", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eran Ben Dor", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Dorit  Amitay", "age": 55, "title": "Vice President of Human Resources", "yearBorn": 1968, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yaron  Turpaz M.B.A., Ph.D.", "age": 52, "title": "Senior VP & Senior Advisor of Data and Informatics Solutions", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Rivka  Schwartz", "title": "Vice President Research and Discovery", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.26, "open": 2.23, "dayLow": 2.09, "dayHigh": 2.25, "regularMarketPreviousClose": 2.26, "regularMarketOpen": 2.23, "regularMarketDayLow": 2.09, "regularMarketDayHigh": 2.25, "beta": 2.679, "forwardPE": -7.344828, "volume": 388381, "regularMarketVolume": 388381, "averageVolume": 622296, "averageVolume10days": 268570, "averageDailyVolume10Day": 268570, "bid": 2.12, "ask": 2.15, "bidSize": 400, "askSize": 200, "marketCap": 202226272, "fiftyTwoWeekLow": 0.53, "fiftyTwoWeekHigh": 3.03, "priceToSalesTrailing12Months": 6.044002, "fiftyDayAverage": 2.4742, "twoHundredDayAverage": 1.46555, "currency": "USD", "enterpriseValue": 141365312, "profitMargins": -0.56051, "floatShares": 84693772, "sharesOutstanding": 89530200, "sharesShort": 2091875, "sharesShortPriorMonth": 1828504, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0234, "heldPercentInsiders": 0.05376, "heldPercentInstitutions": 0.13706, "shortRatio": 3.08, "shortPercentOfFloat": 0.0242, "impliedSharesOutstanding": 94941904, "bookValue": 0.735, "priceToBook": 2.8979592, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -18754000, "trailingEps": -0.21, "forwardEps": -0.29, "enterpriseToRevenue": 4.225, "enterpriseToEbitda": -11.295, "52WeekChange": 2.328125, "SandP52WeekChange": 0.23416412, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CGEN", "underlyingSymbol": "CGEN", "shortName": "Compugen Ltd.", "longName": "Compugen Ltd.", "firstTradeDateEpochUtc": 966000600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "1985262d-ab80-3c43-a2e1-6782924ab738", "messageBoardId": "finmb_166115", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.13, "targetHighPrice": 7.0, "targetLowPrice": 4.0, "targetMeanPrice": 5.33, "targetMedianPrice": 5.0, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 50685000, "totalCashPerShare": 0.566, "ebitda": -12516000, "totalDebt": 1351000, "quickRatio": 4.256, "currentRatio": 4.362, "totalRevenue": 33459000, "debtToEquity": 2.061, "revenuePerShare": 0.382, "returnOnAssets": -0.07536, "returnOnEquity": -0.26186, "freeCashflow": -51053000, "operatingCashflow": -35886000, "revenueGrowth": 3.461, "grossMargins": 0.94011, "ebitdaMargins": -0.37407002, "operatingMargins": 0.53749, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-13"}]